BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jul 14, 2008
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 7/11 cls
Aastrom (NASDAQ:ASTM) Rodman Reni Benjamin Discontinued Market outperform -4% $0.36
The firm dropped coverage of the gene/cell therapy company to reallocate resources.
Acadia (NASDAQ:ACAD) Banc of America Securities William Ho Upgrade Neutral (from sell) -4% $3.28
Ho upgraded because Acadia’s share price fell below his $3.50 target. He doesn’t expect any catalysts until mid-to-late 2009, when he thinks Acadia will have Phase III data from a Parkinson’s disease psychosis (PDP) trial of pimavanserin, a small molecule serotonin (5-HT2A) receptor inverse agonist. Ho also expects the company’s cash to “run critically low” by 2Q09, despite management’s guidance of cash through next year.
Amgen (NASDAQ:AMGN) Deutsche Bank Mark Schoenebaum Price target Buy 0% $51.02
Schoenebaum raised...

Read the full 931 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >